134517-55-8

Basic information

• Product Name: 2,4-DICHLORO-5-CHLOROQUINAZOLINE
• Synonyms: 2,4,5-TRICHLOROQUINAZOLINE;2,4-DICHLORO-5-CHLOROQUINAZOLINE
• CAS NO: 134517-55-8
• Molecular Formula: C₈H₃Cl₃N₂
• Molecular Weight: 233.485
• Product Categories: Heterocycle-Pyridine series
• Mol File: 134517-55-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 309.1±24.0 °C(Predicted)
• Appearance: /
• Density: 1.600±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -1.14±0.30(Predicted)
• CAS DataBase Reference: 2,4-DICHLORO-5-CHLOROQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLORO-5-CHLOROQUINAZOLINE(134517-55-8)
• EPA Substance Registry System: 2,4-DICHLORO-5-CHLOROQUINAZOLINE(134517-55-8)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 134517-55-8(Hazardous Substances Data)

Usage

General Description

2,4-Dichloro-5-chloroquinazoline is a synthetic, organochlorine compound within the quinazoline group of chemicals, known for its wide variety of biological activities. It is not naturally produced, and is often utilised in research, particularly within the fields of pharmaceuticals and biochemistry. Its significance lies in its structural makeup, which enables it to serve as a key intermediate in the synthesis of numerous biologically active compounds. However, there is not much information available concerning the toxicity or environmental impact of this specific chemical.

Upstream product

• 78754-81-1 5-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazoline 
• 2148-56-3 2-chloro-6-aminobenzoic acid 

Relevant articles and documents

SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF

The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses； wherein the compounds or pharmaceutical compositions disclosed herein can be used for antagonizing the orexin receptor. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing neurological and psychiatric disorders and diseases of the central nervous system in mammals, especially in humans.

USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS

Compounds of a compound of compound of general formula (I) wherein X1, X2, A, R1R2, R3 and R4 are as defined herein; are useful as anti-mycobacterial agents, especially agents for the treatment of tuberculosis.

Tricyclic dicarbonyl derivatives

Compounds of general formula (Ia), (Ib) and (II), wherein R1 and R2 each independently signify hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino, halogen, cyano or R3 R4 NS(O)2 -- and R3 and R4 signify lower alkyl, and R2 can additionally signify morpholino or thiomorpholino, a 5- or 6-membered heterocycle with 1-3N atoms optionally substituted by lower alkyl, hydroxy, amino or the group --CH2 NHCH3, a bicyclic heterocycle with 1-3N atoms or a group --NR5 R6 or --OR5 in which R5 and R6 can be the same or different and signify hydrogen, lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, amino-lower alkyl or lower alkylamino-lower alkyl, and X in formula (II) signifies --CH=CH--, --CH=N--, --NH--, --CO-- or --O--, as well as pharmaceutically usable salts of compounds of general formula (Ia), (Ib) and (II). They can be used for the treatment or prevention of illnesses, especially for the treatment or prevention of ischemia, hypoglycaemia, hypoxia, cerebral vascular spasms, spasticity, trauma, hemorrhagia, infection (viral, bacterial, amoebic, prional), epileptic seizures, autoimmune diseases, withdrawal symptoms, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, intoxications, olivoponto-cerebellar atrophy, spinal cord injuries, schizophrenia, depressions, anxiety states, dependence, pains,autism and mental retardation.